Clinical Trial Update: Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Nogapendekin alfa inbakicept with iNKT cell therapy for critically ill adults with severe community-acquired pneumonia, ARDS, and relat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Respiratory Distress Syndrome
• Sepsis

Drugs mentioned

• Nogapendekin-alfa Inbakicept
• iNKT cell therapy (invariant natural killer T cell adoptive transfer)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Status: NOT_YET_RECRUITING